G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 045.65 INR -3.19% Market Closed
Market Cap: 128.1B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Glenmark Life Sciences Ltd
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Glenmark Life Sciences Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Change in Working Capital
-â‚ą3.1B
CAGR 3-Years
-13%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Change in Working Capital
-â‚ą40.2B
CAGR 3-Years
-42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Change in Working Capital
-â‚ą23.7B
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Change in Working Capital
-â‚ą9.6B
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Change in Working Capital
-â‚ą1.1B
CAGR 3-Years
47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Change in Working Capital
-â‚ą4.6B
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Life Sciences Ltd
Glance View

Market Cap
128.1B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

GLS Intrinsic Value
715.71 INR
Overvaluation 32%
Intrinsic Value
Price
G

See Also

What is Glenmark Life Sciences Ltd's Change in Working Capital?
Change in Working Capital
-3.1B INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Change in Working Capital amounts to -3.1B INR.

What is Glenmark Life Sciences Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-21%

Over the last year, the Change in Working Capital growth was 19%. The average annual Change in Working Capital growth rates for Glenmark Life Sciences Ltd have been -13% over the past three years , -21% over the past five years .

Back to Top